Current Cardiology Reports

, 15:327

Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus

Authors

  • Samar Singh
    • Center for Diabetes Research and Treatment and Departments of Medicine, Biological Chemistry, Physiology and BiophysicsUniversity of California
  • Jyoti Bhat
    • Center for Diabetes Research and Treatment and Departments of Medicine, Biological Chemistry, Physiology and BiophysicsUniversity of California
    • Center for Diabetes Research and Treatment and Departments of Medicine, Biological Chemistry, Physiology and BiophysicsUniversity of California
Diabetes and Cardiovascular Disease (S Malik, Section Editor)

DOI: 10.1007/s11886-012-0327-1

Cite this article as:
Singh, S., Bhat, J. & Wang, P.H. Curr Cardiol Rep (2013) 15: 327. doi:10.1007/s11886-012-0327-1
Part of the following topical collections:
  1. Topical Collection on Diabetes and Cardiovascular Disease

Abstract

Over the past several years, there have been a significant number of new agents developed for the treatment of type 2 diabetes. Our goal in this article is to review the cardiovascular effects (risks and benefits) of these oral and non-insulin injectable agents. We review six major categories of diabetic therapies: biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, GLP-1 agonists, and DPP-IV inhibitors. In order to achieve a personalized regimen that aims for optimal outcomes, we must take into consideration each drug’s side effects, patients’ cardiovascular risk factors, and their individual health profile.

Keywords

Type 2 diabetesMedicationsSide effectsOral agentsHeartCardiovascular effects

Copyright information

© Springer Science+Business Media New York 2012